FDA OKs Sanofi/P&G's Actonel with Calcium

21 August 2005

The US Food and Drug Administration has cleared French drugmaker Sanofi-Aventis and USA-based Procter & Gamble Pharmaceuticals' Actonel with Calcium (risedronate sodium/calcium carbonate), which is designed to provide the fracture protection of its predecessor but with the added benefit of conveniently-packaged calcium tablets.

According to the firm, the product, which is marketed by The Alliance for Better Bone Health, a collaboration between the two groups, is the first prescription osteoporosis therapy to include calcium.

"Calcium is a critical component to the effectiveness of osteoporosis therapy," stated Steven Goldstein, professor of obstetrics and gynecology at the New York University School of Medicine. He added: "Actonel with Calcium is an important new tool that helps simplify the osteoporosis regimen by conveniently delivering two important elements - the bisphosphonate and the calcium - in one unique package."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight